885482-99-5Relevant academic research and scientific papers
A kind of deuterium generation 3-cyano-quinoline compound, a pharmaceutically acceptable composition, preparation method and its use
-
, (2016/10/17)
Disclosed in the invention are a deuterated 3-cyano quinoline compound or pharmaceutically acceptable salts, solvates, prodrugs, stereoisomers, tautomers, polymorphic substances, metabolites etc., and a pharmaceutical composition containing such compounds, and the use of these compounds or compositions in the preparation of drugs for treating or preventing tumours, especially drugs such as protein kinase inhibitors. Compared with the prior art, the compounds of the present invention have the clear advantages of properties such as plasma drug concentration, half-life, clearance, microsomal stability, bioavailability or enzyme inhibition and the like, and thus can more effectively inhibit the activities of more than one protein kinase and/or inhibit the growth of tumuor cells.
Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: Identification of SKS-927
Boschelli, Diane H.,Barrios Sosa, Ana Carolina,Golas, Jennifer M.,Boschelli, Frank
, p. 1358 - 1361 (2007/10/03)
Of a series of 7-ethynyl-3-quinolinecarbonitriles, the most potent Src inhibitory activity was observed with 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[4-(4-methylpiperazi n-1-yl)but-1-ynyl]-3-quinolinecarbonitrile (SKS-927). Variation of the so
4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY
-
Page/Page column 17, (2010/11/08)
This invention relates to compounds of the formula (I): wherein: R is methyl or ethyl; R' and R" are independently alkyl of 1 to 3 carbon atoms, or R' and R", taken together with the nitrogen to which they are attached, can form a 5 or 6 membered saturate
